Abstract:Background Anti-angiotensin II receptor subtype 1 (AT1 receptor) autoantibodies have previously been shown in sera of hypertensive patients. This study assessed whether anti-AT1-receptor autoantibody in serum is correlated with the efficacy of an AT1-receptor blocker (ARB; candesartan)-based regimen in hypertensive patients after 8 weeks of treatment.Design The Study of Optimal Treatment in Hypertensive Patients with Anti-AT1-Receptor Autoantibodies is a multicentre, randomised, blinded endpoint, open-label, parallel-group comparison clinical trial conducted in five centres in Wuhan, China. Treatment is designed as stepwise added-on therapy to reduce blood pressure (BP) < 140/90 mm Hg. 512 patients with moderate to severe primary hypertension were randomly assigned to an 8-week treatment with either ARB (candesartan)based regimen (n=257) or ACE inhibitor (imidapril)based regimen (n=255).Results Systolic and diastolic BP was reduced significantly in both treatment groups. The candesartan-based regimen achieved a significantly greater systolic BP reduction than imdapril (30.8+/-10.3 vs 28.8+/-10.3 mm Hg, p=0.023). In those anti-AT1 receptor autoantibody-positive hypertensive patients, the mean systolic BP at baseline was higher than in the anti-AT1 receptor autoantibody-negative group (160.5+/-16.5 vs 156.2+/-17.7 mm Hg; p=0.006). The mean BP reduction was greater in the candesartan-based regimen than the imidapril-based regimen (-35.4+/-9.8/16.9+/-6.9 vs -29.4+/-9.8/14.2+/-6.9 mm Hg; p=0.000 and 0.002, respectively), and more patients on imidapril required add-on medications to achieve BP control (94% vs 86%; p=0.03). No correlation was observed between the titre of anti-AT1 receptor autoantibody and the efficacy of candesartan-based therapy. In those anti-AT1 receptor autoantibody-negative patients similar BP lowering was reached in the candesartan and the imidapril-based regimens.Conclusions An ARB-based regimen is more effective in BP lowering than an ACE inhibitor-based regimen in the presence of anti-AT1 receptor autoantibodies.

Candesartan Inhibits Sinoaortic Denervation-Induced Cardiovascular Hypertrophy in Rats.

Effects of Long-Term Treatment with Candesartan on Organ Damages in Sinoaortic Denervated Rats

Candesartan Suppresses Chronic Renal Inflammation by a Novel Antioxidant Action Independent of AT1R Blockade.

The effect of captopril on endothelin of cardiovascular tissues in spontaneously hypertensive rats

Effects of Long-Term Treatment with Candesartan on Hemodynamics and Organ Damage in Spontaneously Hypertensive Rats

Angiotensin II and AT1 Receptor in Hypertrophied Ventricles and Aortas of Sinoaortic-Denervated Rats.

Candesartan Ameliorates Acute Myocardial Infarction In Rats Through Inducible Nitric Oxide Synthase, Nuclear Factor-B, Monocyte Chemoattractant Protein-1, Activator Protein-1 And Restoration Of Heat Shock Protein 72

Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca 2+ -ATPase activity in rat cardiac pressure-overload hypertrophy

Effects of irbesartan and perindopril on pressure overload-induced cardiac hypertrophy in rats

Candesartan Attenuates Hypertension-Associated Pathophysiological Alterations in the Gut

Candesartan-Induced Gene Expression in Five Organs of Stroke-Prone Spontaneously Hypertensive Rats

Candesartan Prevents the Progression of Glomerulosclerosis in Genetic Hypertensive Rats.

Pretreatment with candesartan protects brain against ischemia in normotensive rats

Effect of the Angiotensin II Receptor Blocker Valsartan on Cardiac Hypertrophy and Myocardial Histone Deacetylase Expression in Rats with Aortic Constriction

Effects of Candesartan on Insulin Sensitivity and Inflammatory Cytokines in Spontaneously Hypertensive Rats

Role of candesartan against cerebral ischemia and oxidative damage in normotensive rats

Candesartan Versus Imidapril in Hypertension: a Randomised Study to Assess Effects of Anti-At1 Receptor Autoantibodies.

Role of Xanthine Oxidoreductase in the Reversal of Diastolic Heart Failure by Candesartan in the Salt-Sensitive Hypertensive Rat

Protective Effect of Candesartan on Podocyte Damage in Rats with Diabetic Nephropathy

The carboxyl group of candesartan contributes to the potent inverse agonist activity and insurmountable inhibition of candesartan

Candesartan Inhibits Inflammation Through an Angiotensin II Type 1 Receptor Independent Way in Human Embryonic Kidney Epithelial Cells